Table of Content



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Microscopic Polyangiitis (MPA) - Overview
Microscopic Polyangiitis (MPA) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Microscopic Polyangiitis (MPA) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development
Biogen Inc
ChemoCentryx Inc
InflaRx NV
Mabion SA
Pharmapraxis
Teijin Pharma Ltd
Microscopic Polyangiitis (MPA) - Drug Profiles
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vilobelimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Microscopic Polyangiitis (MPA) - Dormant Projects
Microscopic Polyangiitis (MPA) - Discontinued Products
Microscopic Polyangiitis (MPA) - Product Development Milestones
Featured News & Press Releases
Jan 30, 2020: The CHMP recommended extensions of indication for MabThera
Sep 30, 2019: Roche’s Rituxan secures approval for first paediatric indication
Jun 12, 2019: FDA grants priority review to Genentech’s Rituxan (Rituximab) in children with two rare blood vessel disorders
Nov 15, 2018: Roche receives positive CHMP opinion to expand MabThera for the treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Desigtion for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
Jun 03, 2014: ChemoCentryx’s CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Desigtion in ANCA-Associated Diseases by the FDA
Mar 22, 2013: Roche Receives CHMP Positive Opinion For MabThera
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures



Number of Products under Development for Microscopic Polyangiitis (MPA), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables



Number of Products under Development for Microscopic Polyangiitis (MPA), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Microscopic Polyangiitis (MPA) - Pipeline by Biogen Inc, H2 2020
Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx Inc, H2 2020
Microscopic Polyangiitis (MPA) - Pipeline by InflaRx NV, H2 2020
Microscopic Polyangiitis (MPA) - Pipeline by Mabion SA, H2 2020
Microscopic Polyangiitis (MPA) - Pipeline by Pharmapraxis, H2 2020
Microscopic Polyangiitis (MPA) - Pipeline by Teijin Pharma Ltd, H2 2020
Microscopic Polyangiitis (MPA) - Dormant Projects, H2 2020
Microscopic Polyangiitis (MPA) - Discontinued Products, H2 2020